INSIG2 and breast carcinoma: Therefore, we speculate that INSIG2, a negative regulator of cholesterol uptake and biosynthesis might possibly when overexpressed in breast cancer by miR-223-5p increases effectiveness of endocrine therapy and eliminate drug resistance.